Evommune Inc (EVMN) News & EventsEVMNEvommune Inc

Evommune's EVO301 Shows Significant Efficacy in Eczema Trial

Evommune shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking oral presentation at the European Academy of Dermatology and Venereology 2026 Congress in Vienna, Austria. EVO301 is a long-acting injectable fusion protein designed to selectively inhibit overactive IL-18, with the potential to offer broader upstream pathway control than standard-of-care biologics. The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg at Baseline and Week 4 with a primary endpoint at Week 12, 8 weeks after the last dose. EVO301 demonstrated a clear therapeutic signal, achieving activity at Week 12 comparable to dose-optimized marketed biologics at Week 16, along with a favorable safety and tolerability profile. In addition, IL-18 inhibition was validated as a novel AD target, with biomarker analyses confirming robust target engagement and broad anti-inflammatory activity across the Th2, Th1, Th17, and Th22 pathways. Data Presentation Highlights: EVO301 met primary endpoint: EVO301 met the trial's primary endpoint, achieving a 55% least-squares mean reduction in EASI from baseline at Week 12 compared with 22% on placebo, eight weeks after the last dose. Statistically significant separation from placebo was observed as early as Week 4 and maintained through Week 8 and Week 12. Early, durable EASI-50 and EASI-75 responses with only two dose administrations: EVO301 demonstrated significant EASI-50 separation from placebo as early as Week 4, with responses sustained and continuing to deepen through Week 12, eight weeks after the last dose. At Week 12, 63% of EVO301-treated patients achieved EASI-50 compared with 23% on placebo, and EASI-75 responses showed increasing separation from placebo over time, reaching 29% vs. 9% on placebo at Week 12, consistent with the range of rates observed with marketed AD biologics after a single dose administered at baseline and Week 4. Optimized pharmacokinetics: EVO301 demonstrated a favorable PK profile consistent with Phase 1 supporting a Q4-week dosing regimen and the potential for every-8-to-12-week maintenance dosing. Mechanistic biomarker evidence: Exploratory analyses showed reductions in the Th2 markers CCL-17 and CCL-22, including approximately 75% reductions in patients with high baseline TARC. EVO301 also reduced Th1, Th17 and Th22 markers, including IL-22, a key regulator of skin barrier function. Favorable safety and tolerability profile: EVO301 was well tolerated, with no treatment-related serious or severe adverse events, no discontinuations due to adverse events, no clinically significant laboratory abnormalities, and no conjunctivitis, a common adverse event reported with AD biologics. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients compared with 13.6% on placebo.

Markets Decline as U.S.-Iran Tensions Rise, S&P 500 Down 0.4%

Markets returned from the extended holiday weekend to familiar macro-oriented concerns - the continued escalation of tensions between U.S. and Iran in the Middle East propping up energy prices while also elevating inflation expectations that are contributing to higher interest rates.   Major indices were down across the board, with Dow Jones Industrials - where Energy is a relatively smaller and Healthcare is a relatively larger contributor vs. S&P 500 - having an outsized 600 point, or 1.2% decline.  S&P 500 - where Energy was the best performing sector and Healthcare was the worst - was predictably down by a much smaller margin of 0.4%, though the index was also boosted by AI capex-specific areas.  The eight best performing stocks in the S&P 500 today, including Lumentum, Intel, and Seagateare all in the AI buildout momentum space.In the opening hour of the evening session index futures are flat, though sentiment is fragile as steady headlines profiling U.S.-Iran hostilities are impacting the oil markets.  WTI crude oil has extended its gains above $94 per barrel, a multi-month high. Precious metals are also under pressure despite USD retreat, with traders likely scaling out of last months' winning trades in preparation for CPI and PPI data this week, which could solidify expectations of a Fed tightening later this month.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -InnovAge Holdingup 9.4%ALSO HIGHER -Chime Financialup 9.2% after acquisition of Stride Bank and raised guidanceDOWN AFTER EARNINGS -ServiceTitandown 20.3%MIND Technologydown 12.9%Brazedown 12.0%Casey's General Storesdown 8.5%Barnes & Noble Educationdown 1.9%ALSO LOWER -Evommunedown 15.1% after EV0756 trial did not meet primary and secondary endpointsTarget Hospitalitydown 6.9% after equity offeringIngram Microdown 5.6% after equity offering

Evommune Shares Drop 31% to $9 After Phase 2b EVO-756 Study Results

Evommune down 31% at $9 after Phase 2b EVO-756 study results